AN2 Therapeutics Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm

Core Viewpoint - AN2 Therapeutics, Inc. is under investigation by Block & Leviton for potential securities law violations following a significant drop in its stock price after announcing a pause in Phase 3 enrollment of its clinical trial for epetraborole [1][2][3]. Group 1: Company Announcement - On February 12, 2024, AN2 Therapeutics announced a pause in Phase 3 enrollment in its seamless Phase 2/3 clinical trial (EBO-301) for epetraborole, pending further data review [2]. - Following this announcement, shares of AN2 Therapeutics dropped more than 70% in premarket trading on the same day [2]. Group 2: Legal Investigation - Block & Leviton is investigating whether AN2 Therapeutics committed securities law violations and may file an action to recover losses for investors [3]. - Investors who have lost money on their AN2 Therapeutics investment are encouraged to contact Block & Leviton for potential recovery options [4]. Group 3: Investor Eligibility - Any individual who purchased common stock of AN2 Therapeutics and has experienced a decline in share value may be eligible to participate in the investigation, regardless of whether they have sold their investment [2].